**TABLE S2.** Characteristics of the included studies.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Species** | **Sex** | **Weight** | **Ischemia duration** | **Reperfusion duration** | **Groups(n)** | **Dosage** | **Route** | **Treatment time** | **Outcome****measure** |
| Cai XB 2011 | SD | Male and Female | 200～250g | 90min | 120min | Control group (n= 12)TMZ group (n= 12) | 0.9%NS 3mg·kg-1·d-1 | i.v | Prior to reperfusion | MDA |
| 3mg·kg-1·d-1  |
| Cheng K 2018 | SD | Male | 180~220g | 30min | 120min | Control group (n= 10)TMZ group (n= 10) | ?20 mg·kg-1·d-1 | i.p | Prior to reperfusion | MDA, LDH, CK-MB |
| Li X 2009 | SD | Male | 150～180g | 60 min | 30min | Control group (n= 8)TMZ group (n= 8) | PW 10 mL·kg-1·d-120 mg·kg-1·d-1 | i.g | Prior to ischemia | SOD, MDA |
| Li XL 2013 | Wistar | Male | 230~280g | 40 min | 120min | Control group (n= 8)TMZ group (n= 8) | 0.9%NS10 mg·kg-1·d-1 | i.g | Prior to ischemia | CK-MB |
| Ruan SF 2013 | Wistar | Male | 230～270g |  30 min | 120min | Control group (n= 10)TMZ group (n= 10) | ?10 mg·kg-1·d-1 | i.g | Prior to reperfusion | LDH, MIS |
| Yu HB 2019 | SD | Male | 280~300g | 45min | 120 min | Control group (n= 10)TMZ group (n= 10) | 0.9%NS10 mg·kg-1·d-1 | i.g | Prior to reperfusion | SOD, MDA  |
| Zhao B 2017 | Wistar | Female | 200~250g | 30min | 120 min | Control group (n= 8)TMZ group (n= 8) | 0.9%NS 10 mg·kg-1·d-110 mg·kg-1·d-1 | i.p | Prior to ischemia | LDH, CK-MB |
| Zhong ZY 2018 | SD | Male | 220～280g | 30 min | 480min | Control group (n= 24)TMZ group (n= 24) | 0.9%NS10 mg·kg-1·d-1 | i.g | Prior to reperfusion | SOD, MDA, CK-MB, MIS |
| Yu HB 2020 | SD | Male | 280～300g | 45min | 120 min | Control group (n= 10)TMZ group (n= 10) | 0.9%NS10 mg·kg-1·d-1 | i.g | Prior to reperfusion | LDH, CK-MB |
| Zhu XM 2018 | SD | Male | 250~300g | 30 min | 120 min | Control group (n= 12)TMZ-L group (n= 12)TMZ-H group (n= 12) | 0.9%NS10 mg·kg-1·d-120 mg·kg-1·d-1 | i.g | Prior to reperfusion | LDH |
| Li XL 2014 | Wistar | Male | 230~280g | 40 min | 120 min | Control group (n= 8)TMZ group (n= 8) | 0.9%NS10mg·kg-1·d-1 | i.g | Prior to ischemia | LDH, MIS |
| Ma N 2016 | SD | Male | 250~300 g | 40 min | 180 min | Control group (n= 25)TMZ group (n= 25) | 0.9%NS 0.1mL·100g-1·d-130mg·kg-1·d-1 | i.p | After reperfusion | LDH, MIS |
| Wu SY 2018 | SD | Male | 160~240g | 30 min | 120 min | Control group (n= 12)TMZ group (n= 12) | 0.9%NS 5ml·kg-1·d-120mg·kg-1·d-1 | i.g | Prior to ischemia | MDA, LDH, CK-MB, MIS |
| (Continued on the following page) |
| **TABLE S2.** (*Continued*) Characteristics of the included studies. |
| **Study** | **Species** | **Sex** | **Weight** | **Ischemia duration** | **Reperfusion duration** | **Groups(n)** | **Dosage** | **Route** | **Treatment time** | **Outcome****measure** |
| Zhou DL 2014 | Wistar | Male and Female | 180~220g | 30 min | 120 min | Control group (n= 10)TMZ-L group (n= 10)TMZ-H group (n= 10) | 0.9%NS10 mg·kg-1·d-120 mg·kg-1·d-1 | i.g | Prior to reperfusion | SOD, MDA |
| Cheng L 2007 | Wistar | Male | 200~250g | 10 min | 30 min | Control group (n= 10)TMZ-L group (n= 10)TMZ-H group (n= 10) | 0.85%NS 2 mL·d-15 mg·kg-1·d-110 mg·kg-1·d-1 | i.g | Prior to ischemia | MDA |
| Fan ZX 2018 | SD | Male | 220～250g | 30 min | 120 min | Control group (n= 10)TMZ-L group (n= 10)TMZ-H group (n= 10) | ？10mg·kg-1·d-120mg·kg-1·d-1 | i.g | Prior to ischemia | LDH |
| Zhou DL 2013 | Wistar | Male and Female | 180～220g | 30 min | 120 min | Control group (n= 8)TMZ-L group (n= 8)TMZ-H group (n= 8) | 0.9%NS10 mg·kg-1·d-120 mg·kg-1·d-1 | i.g | Prior to reperfusion | MIS |
|  |  |  |  |  |
| Khan M 2010 | SD | Male | 300 ~ 350g | 30 min | 60 min | Control group (n= 8)TMZ group (n= 8) | 0.9%NS 0.5 ml·d-15 mg·kg-1·d-1 | i.v | Prior to reperfusion | MIS |
| Kutala VK 2006 | SD | Male | 300 ~ 350g | 30 min | 45 min | Control group (n= 6)TMZ group (n= 6) | ？50 μmol/L | ecp | Prior to ischemia | MIS， LDH |
| Pantos C 2005 | Wistar | Male | 280 ~ 330g | 20 min | 45 min | Control group (n= 9)TMZ-STAB group (n= 8)TMZ-STAB+REP group (n= 8)TMZ-REP group (n= 8) | --10μmol/L10μmol/L10μmol/L | ecp | Prior to ischemiaDuring ischemia and reperfusionDuring reperfusion | LDH |
| Şentürk T 2014 | Wistar | Male | 250 ~ 300g | 30 min | 180 min | Control group (n= 8)TMZ-L group (n= 8)TMZ-H group (n= 8) | NS3 mg·kg-1·d-15 mg·kg-1·d-1 | i.v | During ischemia | MIS, MDA |

(Continued on the following page)

**TABLE S2.** (*Continued*) Characteristics of the included studies.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Species** | **Sex** | **Weight** | **Ischemia duration** | **Reperfusion duration** | **Groups(n)** | **Dosage** | **Route** | **Treatment time** | **Outcome****measure** |
| Kara AF 2004 | Wistar | Male | 220 ~ 320 g | 5 min | 30 min | Control group (n= 24)TMZ group (n= 10) | --10 mg·kg-1·d-1 | i.v | Prior to ischemia | MIS, MDA，CK-MB |
| He WF 2023 | SD | Male | 200～250 g | 30 min | 120 min | Control group (n= 24)TMZ group (n= 10) | NS 20 mg·kg-1·d-120 mg·kg-1·d-1 | i.g | After reperfusion  | MIS, LDH |
| Qiao R 2020 | SD | Male | 220～250 g | 40 min | 120 min | Control group (n= 10)TMZ group (n= 10) | --10μmol/L | ecp | Prior to ischemia and prior to reperfusion | MIS, LDH |

*Abbreviations: TMZ, Trimetazidine; TMZ -L, Trimetazidine low-dose group; TMZ -H, Trimetazidine high-dose group; Control, receiving myocardial ischemic-reperfusion injury group;* *i.p, intraperitoneal injection; i.g, intragastric; i.v, intravenous injection; ecp, extracorporeal perfusion; NS, normal saline; PW, Purified water; SOD, superoxide dismutase; MDA, methane dicarboxylic aldehyde; LDH, lactic dehydrogenase; CK-MB, creatine kinase isoenzyme;* *MIS, myocardial infarct size; ?, not recorded.*